OncoMatch/Clinical Trials/NCT06731270
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Is NCT06731270 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for advanced lung non-small cell carcinoma.
Treatment: Atezolizumab · Cemiplimab · Diclofenac Potassium · Nivolumab · Pembrolizumab — This phase II trial tests how well diclofenac works in treating patients non-small cell lung cancer (NSCLC) that may have spread from where it first started (primary site) to other places in the body (metastatic) on single agent immunotherapy. Diclofenac, a type of non-steroidal anti-inflammatory (NSAID), blocks the body's production of a substance that causes inflammation and may decrease tumor growth and improve the effectiveness of immunotherapy. Immunotherapy with pembrolizumab, atezolizumab, nivolumab or cemiplimab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving diclofenac may kill more tumor cells in patients with metastatic NSCLC on single agent immunotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) PD(L)-1 pathway inhibition
currently on treatment with an FDA approved single agent monoclonal antibody inhibiting the PD(L)-1 pathway (pembrolizumab, atezolizumab, nivolumab, or cemiplimab) for a minimum of 12 weeks
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-PD-1 therapy (pembrolizumab, atezolizumab, nivolumab, cemiplimab) — single agent, ongoing for ≥ 12 weeks
currently on treatment with an FDA approved single agent monoclonal antibody inhibiting the PD(L)-1 pathway (pembrolizumab, atezolizumab, nivolumab, or cemiplimab) for a minimum of 12 weeks; Radiographic evidence of clinical progression as determined by the treating physician
Cannot have received: bevacizumab (bevacizumab)
Treatment within the previous 6 weeks or planned initiation of bevacizumab
Lab requirements
Blood counts
ANC ≥ 1,000 cell/mm^3; Platelets ≥ 100,000 cells/mm^3; Hemoglobin ≥ 8 gm/dL
Kidney function
Creatinine clearance ≥ 45 ml/ml
Liver function
Bilirubin ≤ 1.5 x institutional upper limit of normal (≤ 3 x ULN in Gilbert's syndrome); SGOT/SGPT ≤ 2.5 x ULN
ANC ≥ 1,000 cell/mm^3; Platelets ≥ 100,000 cells/mm^3; Hemoglobin ≥ 8 gm/dL; Creatinine clearance ≥ 45 ml/ml; Bilirubin ≤ 1.5 x institutional upper limit of normal (≤ 3 x ULN in Gilbert's syndrome); SGOT/SGPT ≤ 2.5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Emory University Hospital Midtown · Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify